 NEWARK, Calif., March 22, 2021 PRNewswire -- Protagonist Therapeutics Nasdaq: PTGX Protagonist or the Company announced today that the Division of Nonmalignant Hematology at the U.S. Food and Drug Administration FDA has provided important feedback during an End-of-Phase 2 meeting on rusfertide PTG-300, an investigational new treatment for polycythemia vera PV. 